Immune-Onc Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 22

Immune-Onc Therapeutics General Information

Description

Operator of a private, clinical-stage biopharmaceutical company intended to develop novel therapies in immunology and oncology by targeting myeloid cells. The company has a focused platform approach and differentiated pipeline and has developed first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment, enabling patients to have access to new immunomodulatory.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 795 San Antonio Road
  • Palo Alto, CA 94303
  • United States
+1 (650) 000-0000

Immune-Onc Therapeutics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immune-Onc Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Secondary Transaction - Private 00000 Completed Clinical Trials - Phase 2
9. Later Stage VC (Series B3) 05-Jan-2023 0000 00000 00000 Completed Clinical Trials - Phase 1
8. Grant 20-Apr-2021 000 00000 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series B1) 30-Mar-2021 000.00 00000 00000 Completed Clinical Trials - General
6. Grant 04-Aug-2020 00.000 000.00 Completed Pre-Clinical Trials
5. Grant 01-Aug-2020 00.000 000.00 Completed Pre-Clinical Trials
4. Debt - PPP 13-Apr-2020 000.00 Completed Pre-Clinical Trials
3. Early Stage VC (Series B) 18-Sep-2018 0000 000.00 000.00 Completed Pre-Clinical Trials
2. Accelerator/Incubator 28-Jun-2017 $500K $7.5M Completed Product Development
1. Early Stage VC (Series A) 01-Sep-2016 $7M $7M 0000 Completed Product Development
To view Immune-Onc Therapeutics’s complete valuation and funding history, request access »

Immune-Onc Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B3 00,000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series B2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 20,988,105 $0.000100 6% $1.58 $1.58 1x $1.58 17.37%
Series A 8,634,934 $0.000100 6% $0.81 $0.81 1x $0.81 7.15%
To view Immune-Onc Therapeutics’s complete cap table history, request access »

Immune-Onc Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a private, clinical-stage biopharmaceutical company intended to develop novel therapies in immunology and on
Drug Discovery
Palo Alto, CA
29 As of 2024
00000
000000 - 000 00000

00000

t ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exerci
0000 000000000
Nahariya, Israel
00 As of 0000
000.00
000.00 0000-00-00
00000000000 000.00

000000

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000000000000
Beltsville, MD
00 As of 0000
00000
00000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immune-Onc Therapeutics Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biond Biologics Venture Capital-Backed Nahariya, Israel 00 000.00 00000000000 000.00
NextCure Formerly VC-backed Beltsville, MD 00 00000 00000000 00000
MacroGenics Formerly VC-backed Rockville, MD 000 00000 000000000 00000
Lyell Immunopharma Formerly VC-backed South San Francisco, CA 000 00.000 00000000 00.000
BioLegend Formerly Accelerator/Incubator backed San Diego, CA 000 000000&0
You’re viewing 5 of 36 competitors. Get the full list »

Immune-Onc Therapeutics Patents

Immune-Onc Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021365142-A1 Novel anti-lilrb2 antibodies and derivative products Pending 21-Oct-2020 00000000000
CA-3198844-A1 Novel anti-lilrb2 antibodies and derivative products Pending 21-Oct-2020 00000000000
EP-4232087-A1 Novel anti-lilrb2 antibodies and derivative products Pending 21-Oct-2020 00000000000
US-20240002503-A1 Novel anti-lilrb2 antibodies and derivative products Pending 21-Oct-2020 00000000000
AU-2021365142-A9 Novel anti-lilrb2 antibodies and derivative products Pending 21-Oct-2020 C07K16/2803
To view Immune-Onc Therapeutics’s complete patent history, request access »

Immune-Onc Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Charlene Liao Ph.D Co-Founder, Chief Executive Officer, President & Chairman
Christopher Whitmore Chief Financial Officer
Hong Xiang Ph.D Chief Development Officer
Guoliang Yu Ph.D Co-Founder & Board Member
Chengcheng Zhang Ph.D Scientific Founder
You’re viewing 5 of 9 executive team members. Get the full list »

Immune-Onc Therapeutics Board Members (9)

Name Representing Role Since
Austin Gurney Ph.D Self Board Member 000 0000
Barbara Klencke MD Self Board Member 000 0000
Charlene Liao Ph.D Immune-Onc Therapeutics Co-Founder, Chief Executive Officer, President & Chairman 000 0000
Dave Chenn Oceanpine Capital Board Member 000 0000
Feng Deng Northern Light Venture Capital Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Immune-Onc Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immune-Onc Therapeutics Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brightway Future Capital Venture Capital Minority 000 0000 000000 0
Proxima Ventures (China) Venture Capital Minority 000 0000 000000 0
Triwise Capital Venture Capital Minority 000 0000 000000 0
Wuxi Biologics Corporation Minority 000 0000 000000 0
Leukemia & Lymphoma Society Not-For-Profit Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 22 investors. Get the full list »

Immune-Onc Therapeutics FAQs

  • When was Immune-Onc Therapeutics founded?

    Immune-Onc Therapeutics was founded in 2016.

  • Who is the founder of Immune-Onc Therapeutics?

    Charlene Liao Ph.D, Guoliang Yu Ph.D, and Chengcheng Zhang Ph.D are the founders of Immune-Onc Therapeutics.

  • Who is the CEO of Immune-Onc Therapeutics?

    Charlene Liao Ph.D is the CEO of Immune-Onc Therapeutics.

  • Where is Immune-Onc Therapeutics headquartered?

    Immune-Onc Therapeutics is headquartered in Palo Alto, CA.

  • What is the size of Immune-Onc Therapeutics?

    Immune-Onc Therapeutics has 29 total employees.

  • What industry is Immune-Onc Therapeutics in?

    Immune-Onc Therapeutics’s primary industry is Drug Discovery.

  • Is Immune-Onc Therapeutics a private or public company?

    Immune-Onc Therapeutics is a Private company.

  • What is Immune-Onc Therapeutics’s current revenue?

    The current revenue for Immune-Onc Therapeutics is 000000.

  • How much funding has Immune-Onc Therapeutics raised over time?

    Immune-Onc Therapeutics has raised $138M.

  • Who are Immune-Onc Therapeutics’s investors?

    Brightway Future Capital, Proxima Ventures (China), Triwise Capital, Wuxi Biologics, and Leukemia & Lymphoma Society are 5 of 22 investors who have invested in Immune-Onc Therapeutics.

  • Who are Immune-Onc Therapeutics’s competitors?

    Biond Biologics, NextCure, MacroGenics, Lyell Immunopharma, and BioLegend are some of the 36 competitors of Immune-Onc Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »